In a report released today, Ivan Feinseth from Tigress Financial reiterated a Buy rating on CVS Health (CVS – Research Report), with a price target of $108.00. The company’s shares closed last Thursday at $82.63.
According to TipRanks.com, Feinseth is a top 100 analyst with an average return of 19.9% and a 71.2% success rate. Feinseth covers the Technology sector, focusing on stocks such as Alphabet Class A, Cisco Systems, and Microsoft.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVS Health with a $96.41 average price target, representing a 16.7% upside. In a report issued on July 20, Cowen & Co. also maintained a Buy rating on the stock with a $105.00 price target.
See today’s analyst top recommended stocks >>
Based on CVS Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $69.1 billion and net profit of $2.22 billion. In comparison, last year the company earned revenue of $66.76 billion and had a net profit of $2.01 billion.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CVS in relation to earlier this year. Most recently, in May 2021, Thomas Moriarty, the EVP & GC of CVS bought 49,279 shares for a total of $2,874,937.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.
Read More on CVS:
